Skip to main content

Table 1 Clinical characteristics at the baseline of Pegasys treatment

From: Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid

 

Case 1

Case 2

Case 3

Age (yr)

23

54

42

Course of disease (yr)

6

2

17

HBV genotype

B

C

B

HBeAg

+

-

-

Anti-HBe

-

+

+

HBV DNA (Lc/ml

7.78

6.90

6.99

WBC x 10/L

7.5

5.89

5.69

Hb (g/L)

156

137

152

Plt( x 10/L

135

112

101

ALT (lU/L)

333

71

304

AST (lU/L)

215

76

149

AST/ALT ratio

0.65

1.07

0.49

ALP (lU/L)

197

123

94

y-GTP(lU/L

45

27

44

Total bilirubin(umol/L

13.9

16.9

30.9

Prothrombin activity (%)

105

100

104

AFP (ng.ml)

3.31

5.6

4.29

Creatinine ( μmol/L)

59

79

81

T3 free (pmol/L)

4.1

3.9

3.6

T4 free (pmol/L)

14.3

11.3

12.7

TSH (mlU/L

2.1

1.2

1.4

Fibroscan (kPa)

4.3

5.1

5.7

  1. yr: year; Course of disease: interval between the first time when HBsAg-positive was detected and the date before treatment; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; LC/ml: Log copies/ml; WBC: white blood cell; Hb: hemoglobin; Plt: platelet; ALT: alanine aminotransferase; AST: asparate aminotransferase; ALP: alkaline phosphatase; γ-GTP: gamma glutamil transpeptidase; AFP: alpha fetoprotein; T3 and T4: thyroxin 3 and 4; TSH: thyroid-stimulating hormone.